Connect with us

Hi, what are you looking for?

Wednesday, Jun 19, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Filament Health to list on Nasdaq through new business arrangement

The transaction is expected to close in Q4 this year

Filament Health to list on Nasdaq through new business arrangement
Photo via Filament Health

Vancouver-based Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) will soon be listed on the Nasdaq exchange through a new business arrangement expected to accelerate the progression of its psychedelic drug development capabilities.

The company announced the transaction on Wednesday which is expected to close in Q4 this year. The upcoming Nasdaq listing will be possible through the formation of a separate combined company with Jupiter Acquisition Corporation (NASDAQ: JAQC), a publicly listed entity created solely for acquisitions and mergers with other businesses.

Filament says the business combination provides it with US$176 million in equity value, representing US$0.85 per company share. The new company will have an estimated total value/pro forma enterprise valuation of US$210 million.

“Today’s announcement is an important milestone for Filament as we gain access to the broader capital markets needed to advance our drug development platform,” said Filament’s CEO Benjamin Lightburn.

“We are thrilled to have the opportunity to impact the advancement of psychedelic medicines that will support the treatment of mental health conditions through this combination with Filament,” said Jupiter’s CEO James Hauslein, adding that the deal was expected to be a value driver for Jupiter shareholders.

Read more: Numinus Wellness reports 12.6% sequential revenue growth to $6M

Read more: Majority of Americans support regulating psychedelics: UC Berkeley survey

Filament also announced Wednesday that it will be receiving a $2 million non-brokered private placement from Negev Capital, a financial firm that describes itself as a psychedelic medical intervention investment fund.

The funds will be utilized by Filament for general corporate expenses and an FDA-approved Phase II clinical trial aimed at treating methamphetamine use disorder with psilocybin.

“With vertically integrated manufacturing capabilities creating standardized, botanical drug candidates, Filament is poised to succeed,” said Negev’s Partner Ken Belotsky, adding that Filament was one of the most compelling early-stage companies in the psychedelics industry and that its treatments could help millions of people.

Earlier this month, Filament licensed its patented psilocybin drug PEX010 to Burnaby’s NeoLumina Bioscience to be used as a potential treatment for eating disorders. Filament will be receiving milestone payments and commercial royalties for providing NeoLumina with intellectual property rights through the deal.

The company will also be supplying psilocybin to the Canadian government for a series of upcoming clinical trials valued at $3 million. The trials will study the psychedelic’s potential for the treatment of mental health and substance use disorders.

Filament’s cash position decreased significantly year-over-year at the end of 2022, dropping by approximately $1.8 million or 38.5 per cent to $2.85 million.

The company’s stock rose significantly by 46.83 per cent Wednesday to US$0.095 on the OTC markets.

Jupiter shares stayed flat at US$10.22 on the Nasdaq stock exchange.


Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Despite rejection from the advisory committee, the FDA won't make its final decision on the matter until August


BC's mushroom expert got an MDMA export permit for shipments to Israel this month too


The Department of Veteran Affairs, or VA, is quietly working on getting ecstasy approved for therapeutic use


Research shows that substances like Psychedelics like LSD, DMT and magic mushrooms can be used in medicine